Ionetix Produces First Alpha-Emitting Radionuclide at New Isotope Production Facility
LANSING, Mich., Jan. 26, 2022 /PRNewswire/ -- IONETIX Corporation, an innovative, end-to-end radiopharmaceutical solution provider focusing on establishing a secure supply chain for alpha-emitting radiopharmaceuticals today announced it has signed a supply agreement for the therapeutic radioisotope astatine-211 (211At) with Precision Molecular, Inc. (PMI), a clinical-stage company developing targeted radiopharmaceuticals and theranostics for patients with cancer.